Compare BioNano Genomics Inc (BNGO) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs NetApp Inc. — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while NetApp Inc. trades at $199.52 (market cap $38.95B). The key difference: NetApp Inc. is far larger — about 2851.4× BioNano Genomics Inc's market cap, and NetApp Inc. pays a 1.05% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | NTAP | |
|---|---|---|
Market Cap | $13.66M | $38.95B |
Sector | Health | Technology |
52-Week High | $4.92 | $198.72 |
52-Week Low | $1.06 | $94.11 |
Enterprise Value | $16.26M | $38.10B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
NetApp (NTAP) trades at $198.72, up 4.85% today, near its consensus price target high of $200. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue grew to $6.57B in 2025 with an 18.43% net margin, while acquisitions like JetStream Software and DataPelago enhance its AI infrastructure capabilities. Cash flow turned positive at $840M in 2025 after two years of negative net flows.
Outlook is positive given earnings consistency and strategic AI investments, but high valuation ratios (P/E 31.26) and overbought RSI levels near 85 pose near-term risks. Analyst consensus leans Hold (50.7%), suggesting cautious optimism amid growth execution and competitive pressures in data storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
